Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have a cancer tumor, with a change in the KRAS G12C gene, that is advanced and/or has spread to another part of the body
Be well enough to walk and do light work
Have adequate organ function and blood counts, as measured by blood tests
Have stopped all cancer treatment and have recovered from the major side effects
Be able to swallow capsules and/or tablets
Participants Must Not:
Have cancer that can be cured with treatments that target a specific part of the body (like surgery or radiation)
Have active infection or a serious medical condition (other than this cancer)
Have had another type of cancer within the last three years
Have cancer that has spread to the brain or spinal cord and is causing symptoms except for one part of the study
Have already had treatment with a drug that works in the same way as this study drug, except for certain patients with lung cancer
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo